Segall Bryant & Hamill LLC Trims Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX

Segall Bryant & Hamill LLC cut its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 7.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,134,813 shares of the biotechnology company’s stock after selling 85,264 shares during the period. Segall Bryant & Hamill LLC owned about 0.54% of BioCryst Pharmaceuticals worth $8,613,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership raised its stake in shares of BioCryst Pharmaceuticals by 2,103.7% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company’s stock valued at $38,336,000 after buying an additional 4,084,403 shares during the last quarter. Qube Research & Technologies Ltd grew its holdings in BioCryst Pharmaceuticals by 152.3% during the second quarter. Qube Research & Technologies Ltd now owns 2,373,489 shares of the biotechnology company’s stock worth $21,266,000 after acquiring an additional 1,432,824 shares during the period. Bank of America Corp DE raised its position in BioCryst Pharmaceuticals by 97.9% during the second quarter. Bank of America Corp DE now owns 2,841,155 shares of the biotechnology company’s stock valued at $25,457,000 after acquiring an additional 1,405,498 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in BioCryst Pharmaceuticals by 1,059.7% in the second quarter. BNP Paribas Financial Markets now owns 1,456,857 shares of the biotechnology company’s stock valued at $13,053,000 after acquiring an additional 1,331,230 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in BioCryst Pharmaceuticals by 6.1% in the third quarter. Vanguard Group Inc. now owns 21,790,881 shares of the biotechnology company’s stock valued at $165,393,000 after acquiring an additional 1,246,633 shares during the period. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $8.57 on Thursday. The firm has a fifty day moving average of $7.20 and a 200 day moving average of $7.40. The firm has a market cap of $2.15 billion, a PE ratio of 7.14 and a beta of 0.74. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $1.05. The business had revenue of $163.28 million for the quarter, compared to the consensus estimate of $151.32 million. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 84.33%. The company’s revenue was up 209.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.13) earnings per share. On average, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BCRX has been the topic of a number of analyst reports. Royal Bank Of Canada dropped their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, January 30th. HC Wainwright raised their price target on shares of BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, December 29th. Citizens Jmp decreased their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a research report on Wednesday, November 5th. Finally, Evercore began coverage on BioCryst Pharmaceuticals in a research report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 target price on the stock. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $19.64.

Insiders Place Their Bets

In related news, insider Alane P. Barnes sold 21,773 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $7.65, for a total value of $166,563.45. Following the sale, the insider directly owned 398,751 shares in the company, valued at approximately $3,050,445.15. The trade was a 5.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.10% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.